Kimberly Brown, MD, is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University
Medical experts discuss the management of patients with hepatic encephalopathy (HE) receiving lactulose and rifaximin therapy and develop diarrhea or a urinary tract infection (UTI) in the outpatient setting.
The expert panel on hepatic encephalopathy (HE) presents clinical recommendations for managing patients with recurrent or episodic HE in the outpatient setting.
The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.
Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.
Kimberly Brown, MD, explains the role of the gut microbiota in the development of hepatic encephalopathy (HE) and describes the common alterations to the microbiota that occur because of chronic liver disease.
Arun B. Jesudian, MD, discusses strategies to prevent the progression of cirrhosis, which include targeting microbiome abnormalities to improve the gut-liver axis, enhancing circulatory function, treating the inflammatory state, and addressing portal hypertension.
The panel examines the evolving role of primary care clinicians in managing patients with hepatic encephalopathy (HE) and emphasizes the importance of consulting specialists when necessary, providing insights from the perspective of a primary care clinician.
The expert panelists explore the symptoms and risk factors associated with HE, the challenges in diagnosing the condition due to its resemblance to neuropsychiatric l disorders, and the methods used to assess and grade the severity of the disease.
Medical experts emphasize the importance of educating primary care clinicians about the outpatient management of hepatic encephalopathy, a common complication of portal hypertension, and highlight the crucial role of ammonia testing in effectively managing the disease.
Pamela Kushner, MD, FAAFP; Nancy Reau, MD; Arun B. Jesudian, MD, and Kimberly Brown, MD, discuss the impact of hepatic encephalopathy (HE) on patients and their families, as well as strategies for improving patient outcomes.
Hepatology experts discuss educating patients with hepatic encephalopathy on managing medications and supplements.
Kimberly A. Brown, MD, shares approaches to educating patients on management of hepatic encephalopathy and the importance of medication adherence and nutrition.
Expert hepatologists comment on primary care providers using rifaximin to manage and prevent episodes of hepatic encephalopathy.
Arun B. Jesudian, MD, and Kimberly A. Brown, MD, highlight clinical trial data of rifaximin for the treatment of hepatic encephalopathy.
Kimberly A. Brown, MD, reviews the use of lactulose and rifaximin as first-line treatment of hepatic encephalopathy.
Arun B. Jesudian, MD, and Kimberly A. Brown, MD, discuss conditions that may be mistaken for hepatic encephalopathy.
Experts in hepatology comment on effectiveness of diagnostic testing hepatic encephalopathy.
Expert hepatologists discuss how to identify patients with hepatic encephalopathy who require hospitalization vs outpatient care.
Kimberly A. Brown, MD, comments on the life-threatening nature of recurrent HE and how to navigate patient conversations.
Experts in hepatology discuss the pathophysiology of HE and how certain factors influence the brain in HE.
Kimberly A. Brown, MD, reviews classifying the severity of HE and defines covert vs overt HE.
Arun B. Jesudian, MD, and Kimberly A. Brown, MD, provide an overview of hepatic encephalopathy, signs and symptoms, and underlying liver disease as a major risk factor.
